Peptide-assisted systemic delivery of therapeutic antisense oligonucleotides in a spinal muscular atrophy model
Spinal muscular atrophy (SMA) is a neurodegenerative disease caused by homozygous loss of the survival motor neuron 1 (SMN1) gene. It results in progressive atrophy of voluntary muscle groups leading to paralysis and eventually premature infantile death.
Humans have a second, nearly identical copy of the SMN1 gene, SMN2. The 90% majority of SMN2 transcripts lack exon-7, which leads to the production of a truncated SMN protein that is highly unstable. Therefore, increasing the expression of full-length functional SMN protein by forcing SMN2 exon-7 inclusion is a rational therapeutic development for SMA patients.
Antisense oligonucleotides (ASO) targeting SMN2 exon 7 inclusion have been developed, which inhibit binding of small nuclear ribonucleic proteins (snRNPs) and can restore full-length SMN2, leading to the production of functional SMN protein. However, the delivery of ASO to the spinal motor neurons remains a challenge. In this project, we will develop a peptide-based delivery system that can shuttle ASO to the spinal cord using an axonal retrograde transport system.
Project plan
- Synthesis of targeted axonal import (TAxI) peptide and conjugation to ASO.
- Validation of the peptide-ASO in SMA patient-derived fibroblast for SMN2 splice correction using RT-qPCR.
- Intramuscular (gastrocnemius) injection of peptide-ASO in Δ7SMA mice. Analysis of spinal cord for full-length SMN2 upregulation using RT-qPCR and western blot analysis.
Research team
Supervisor
Research group
Take part in this project
Student applications
Students who are applying to study at The Florey can register their interest in this project. Refer to our step-by-step guide to help you with your application.
Contact us
If you’re interested in learning more about this project please contact our team.
